Navigation Links
Amicus Therapeutics Opens Research Facility in San Diego
Date:9/15/2008

CRANBURY, N.J. and SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that the company has leased laboratory space for a focused, small scale research facility in San Diego. The facility will be used to support ongoing research into new applications of the company's platform technology.

"With proof of concept for pharmacological chaperones now established, research at the San Diego facility will support Amicus' efforts to expand our early stage pipeline," said David Lockhart, Ph.D., chief scientific officer for Amicus Therapeutics. "Locating the new laboratory in San Diego allows us to complement and expand our existing research capabilities in Cranbury by tapping into the significant resources and expertise of the San Diego science and biotechnology community."

"We believe pharmacological chaperones have significant potential to treat a broad range of genetic diseases," added John Crowley, president and CEO of Amicus. "The focus of our research efforts in San Diego will be to assess new chaperone applications in diseases with high unmet medical needs and larger patient populations particularly in the areas of neurodegenerative and metabolic disorders. This small scale facility will complement our core research and development activities in New Jersey."

The new laboratory space was included in Amicus' operating plan and budget for 2008 as part of increased investment in research beyond the lysosomal storage disorders. Amicus expects to begin occupying the space immediately.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to Amicus Therapeutics' research and discovery programs. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the potential scope, progress, timing and outcomes of the company's research and discovery programs, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of research, discovery and pre-clinical studies indicate that the product candidates are unsafe or ineffective; and, our dependence on third parties in the conduct of our research and discovery efforts; further, the results of earlier research and discovery efforts, pre-clinical studies and clinical studies may not be predictive of future results; and other risks detailed in our annual Report on Form 10-K for the year ended December 31, 2007, and our other public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FOLD-G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... NEWTOWN SQUARE, Pa. , June 20, 2017 /PRNewswire/ ... technology, is pleased to announce the issuance of a ... treating gout or hyperuricemia by the U.S. Patent and ... Biotech Inc., a winner of the Buzz of Bio ... , is akin to developing non-drug approaches to ...
(Date:6/20/2017)... ... June 20, 2017 , ... Do More with OHAUS , With the launch ... supplier in the weighing industry, to extending its expertise across the entire laboratory to ... hybridizations and more, allowing for its customers to 'Do More' in the ...
(Date:6/19/2017)... ... June 19, 2017 , ... As ... supporting EDETEK’s products including training, implementation, support, and client process and SOP development. ... He has previously held leadership roles for service providers and top-tier pharmaceuticals, and ...
(Date:6/19/2017)... ... June 19, 2017 , ... Tunnell Consulting ... 50 years. One of the biggest challenges faced by life sciences, biotech and pharmaceuticals ... services team is Kati Abraham , who is well known in the industry ...
Breaking Biology Technology:
(Date:3/22/2017)... , March 21, 2017 Optimove ... used by retailers such as 1-800-Flowers and AdoreMe, ... — Product Recommendations and Replenishment. Using Optimove,s machine learning ... personalized product and replenishment recommendations to their customers ... on predictions of customer intent drawn from a ...
(Date:3/20/2017)... March 20, 2017 At this year,s CeBIT Chancellor ... biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with ... this year,s CeBIT partner country. At the largest German biometrics company the ... fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification ... Used combined in one project, multi-biometric solutions provide a ... ...
Breaking Biology News(10 mins):